ZN-C3 + niraparib

**ZN-C3 + niraparib** is a combination therapy under clinical investigation for **platinum-resistant ovarian cancer** and related gynecological cancers.\n- **ZN-C3** is an orally administered small molecule inhibitor targeting **WEE1 kinase**, a regulator of the G2/M cell cycle checkpoint. Inhibition of WEE1 kinase can lead to unscheduled entry into mitosis and apoptosis in cancer cells, especially those with defects in DNA repair mechanisms[5].\n- **Niraparib** is a **poly (ADP-ribose) polymerase (PARP) inhibitor**—specifically inhibiting PARP-1 and PARP-2—which plays a crucial role in DNA damage repair. Its inhibition promotes synthetic lethality in cancer cells with homologous recombination deficiency, including BRCA mutations[2][4].\n- The combination is designed to synergistically impair DNA damage response: ZN-C3 induces cell cycle progression and DNA damage, while niraparib blocks DNA repair, leading to increased cancer cell death[5][3][1].\n- The combination is administered orally, both drugs being given together, and is currently in Phase 1/2 clinical trials sponsored by Zentalis Pharmaceuticals and collaborators, targeting platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer[1][3][5].

Brand names

Zejula

Other names

ZN-c3 + niraparibZEJULA + ZN-C3